For severe diarrhea-predominant irritable bowel syndrome (IBS). ANDA 211621, held by Adaptis. Alosetron Hydrochloride.
As of Nov 16, 2026, ANDA 211621 (Alosetron Hydrochloride), held by Adaptis, was first approved by FDA on Sep 16, 2019, with 2 approved supplements and 0 published complete response letters.
Alosetron tablets are indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 16, 2019 | Original application | Approved | None posted |
| Alosetron HydrochlorideEQ 0.5MG BASE · tablet;oral | Alosetron Hydrochloride | Rx |
| Alosetron HydrochlorideEQ 1MG BASE · tablet;oral | Alosetron Hydrochloride | Rx |
| Aug 15, 2025 | Supplement 2Manufacturing | Approved | None posted |
| Sep 8, 2023 | Supplement 1REMS | Approved | |
| Sep 16, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters